Kymera Therapeutics, Inc.KYMRNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+23.1%
5Y CAGR+37.1%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+23.1%/yr
vs +76.5%/yr prior
5Y CAGR
+37.1%/yr
Recent deceleration
Acceleration
-53.3pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
4.8x
Strong expansion
Streak
7 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $388.60M | +25.9% |
| 2024 | $308.71M | +26.5% |
| 2023 | $244.12M | +17.3% |
| 2022 | $208.08M | +20.0% |
| 2021 | $173.36M | +115.8% |
| 2020 | $80.34M | +78.0% |
| 2019 | $45.14M | +110.4% |
| 2018 | $21.45M | - |